---
title: "VK2735 in Chronic weight management: VENTURE"
description: "Formulary evidence on VK2735 in Chronic weight management: VENTURE. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 73 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence/venture"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: VENTURE

<a id="heading-3.1.5"></a>

## 3.1.5 VENTURE

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Dose finding for weight loss over 13 weeks to inform phase 3

> “This study aimed to determine doses of VK2735, a novel glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide (GLP‐1/GIP) receptor dual agonist, that are effective for weight loss over 13 weeks of treatment.”
> “The VENTURE study was a 13‐week, dose‐ranging study designed to provide preliminary efficacy and safety data for subcutaneous VK2735 as a treatment for obesity to inform phase 3 study design.”
> “The main objectives of the VENTURE study were to evaluate the safety, tolerability, and weight loss efficacy of VK2735.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.1-2"></a>

#### Registered objectives: safety, tolerability, efficacy, pharmacodynamics, and pharmacokinetics

> “This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.”

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Twenty sites in the United States, August 2023 to February 2024

> “VENTURE was a phase 2, 13‐week, randomized, double‐blind, placebo‐controlled, parallel‐arm, dose‐finding study conducted in 20 sites in the United States.”
> “The trial was conducted between August 31, 2023, and February 23, 2024.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.2-2"></a>

#### Registered study dates

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2023-08-31” |
| Primary completion (actual) | “2024-02-27” |
| Study completion (actual) | “2024-04-02” |

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="topic-3.1.5.2-3"></a>

#### Topline results announced in February 2024

> “SAN DIEGO, Feb. 27, 2024 /PRNewswire/”
> “The Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo.”

Source: [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Randomized, double-blind, placebo-controlled, parallel-arm, dose-ranging design

> “VENTURE was a phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study of weekly subcutaneous VK2735 in adults with obesity or overweight and ≥ 1 weight‐related comorbidity.”
> “The total study duration was 23 weeks, comprising a 4‐week screening period, a 13‐week treatment period, and an approximately 6‐week safety follow‐up period (Figure S1).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.3-2"></a>

#### Central randomization and blinding

> “All participants were centrally assigned to a randomized study intervention using an Interactive Web Response System (IWRS).”
> “Once deemed eligible for enrollment in the study, participants were assigned a sequential randomization number prior to first dosing.”
> “The investigators and study staff were blinded to each participant's assigned study intervention throughout the course of the study.”
> “Subcutaneous injections were matched for volume for placebo and active treatment groups.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.3-3"></a>

#### Registered design and masking

| Field | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Triple” |

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Adults with obesity, or overweight with a weight-related comorbidity, without diabetes

> “Eligible participants were over the age of 18 years, with BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 and at least one weight‐related comorbid condition (treated or untreated).”
> “Weight‐related comorbid conditions include hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease.”
> “Participants with BMI > 50 kg/m2 or with certain medical conditions, including diabetes, were not eligible.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.4-2"></a>

#### Registered inclusion criteria

> “Age ≥18 years of age at the time of signing the informed consent”
> “Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI <50 kg/m2”

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="topic-3.1.5.4-3"></a>

#### Registered exclusion criteria: diabetes, pancreatitis, calcitonin, and prior incretin or weight-loss drugs

> “Self-reported body weight change of 5% or more within 3 months of screening”
> “Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)”
> “Current or past diagnosis of chronic pancreatitis”
> “Calcitonin ≥20 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)”
> “Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening”
> “Any prescription or over-the-counter medications intended for weight loss within 6 months of screening”

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Four weekly subcutaneous doses or matched placebo, randomized 1:1:1:1:1

> “Participants who met eligibility criteria were randomized to one of four VK2735 weekly subcutaneous injection treatment groups (2.5, 5.0, 10, or 15 mg) or the matched placebo injection group in a 1:1:1:1:1 ratio on day 1 (Figure S1 and Table S1).”
> “Placebo injections were matched for volume.”
> “Titration to final dose was conducted as shown in Figure S1 for the active treatment groups.”
> “Fasting was not otherwise required for dosing.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.5-2"></a>

#### Titration schedule to the final dose in each arm

| Dose arm | Titration schedule |
| --- | --- |
| VK2735 2.5 mg | “2.5 mg cohort = 2.5 x 13 weeks” |
| VK2735 5 mg | “5 mg cohort = 2.5 mg x 3 wks, 5 mg x 10 wks” |
| VK2735 10 mg | “10 mg cohort = 2.5 mg x 3 wks, 5 mg x 3 wks, 7.5 mg x 3 wks, 10 mg x 4 wks” |
| VK2735 15 mg | “15 mg cohort = 5 mg x 3 wks, 7.5 mg x 3 wks, 10 mg x 3 wks, 15 mg x 4 wks” |

Source: [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="topic-3.1.5.5-3"></a>

#### Starting dose of 5.0 mg in the 15 mg arm

> “Nausea was highest in the first week in the 15 mg dose group; this group had a 5.0 mg starting dose, rather than the 2.5 mg starting dose in all other treatment groups (Figure 3 and Figure S1).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.5-4"></a>

#### Background diet and exercise counseling in all arms

> “All participants were encouraged to exercise for approximately 150 min per week and reduce daily intake by 500 kcal.”
> “Instructional materials were provided at Week 0 (i.e., randomization), and counseling sessions were conducted at study sites at Week 3, Week 6, and Week 9 (Table S1).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.5-5"></a>

#### Registered intervention description

> “VK2735 is a peptide GLP-1 and GIP dual agonist”

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Percent Change in Body Weight as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

##### Primary, secondary, and exploratory efficacy endpoints

> “The primary endpoint was percent (relative) change from baseline to Week 13 in body weight.”
> “Secondary efficacy endpoints were observed and change from baseline to Week 13 in body weight and the proportion of participants losing ≥ 5% and 10% of baseline weight at Week 13.”
> “The proportion of participants losing ≥ 15% of baseline weight was an exploratory objective.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.6.1-2"></a>

##### Safety endpoints

> “Safety endpoints included incidence of treatment‐emergent adverse events (TEAEs), treatment‐emergent serious adverse events (TESAEs), and adverse events of special interest.”
> “Changes in vital signs and the proportion of participants with anti‐drug antibodies were also evaluated.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.6.1-3"></a>

##### Exploratory glycemic, cardiometabolic, and anthropometric endpoints

> “Key exploratory endpoints included effects of VK2735 on glycemic status, cardiometabolic parameters, and anthropometric parameters.”
> “Categories of glycemic control were defined by fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) as: normoglycemic = FPG < 100 mg/dL and HbA1c < 5.7%, prediabetes = FPG 100–125 mg/dL or HbA1c 5.7%–6.4%, and diabetes = FPG > 125 mg/dL or HbA1c > 6.4%.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.6.1-4"></a>

##### Metabolic syndrome definition used in the exploratory analysis

> “Defined as the presence of three or more metabolic abnormalities such as: a) waist circumference of more than 40 inches in men and 35 inches in women; b) serum triglycerides level of 150 mg/dL or greater; c) high-density lipoprotein cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women; d) elevated fasting glucose of l00 mg/dL or greater; e) systolic blood pressure of 130 mm Hg or higher or diastolic blood pressure of 85 mm Hg or higher.”

Source: [Viking Therapeutics ObesityWeek 2025 release (2025)](https://ir.vikingtherapeutics.com/2025-11-06-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-in-Presentation-at-ObesityWeek-R-2025)

<a id="topic-3.1.5.6.1-5"></a>

##### Registered outcome measures

| Outcome role | Quoted record |
| --- | --- |
| Primary | “Percent (relative) change from baseline to Week 13 in body weight” |
| Secondary | “Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13” |
| Other | “Incidence of treatment-emergent adverse events (TEAEs), TESAEs, AESI” |

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="topic-3.1.5.6.1-6"></a>

##### Weight reduction and its association with morbidity, mortality, and health care spending

> “Interventional and epidemiological studies support that reduction of excess body weight reduces morbidity and mortality, and that this reduction is correlated with the magnitude of weight loss”
> “Weight loss of as little as 5%–10% is associated with a reduction in new onset type 2 diabetes and some cancers and improvements in sleep apnea, hypertension, dyslipidemia, hyperglycemia, osteoarthritis of the knee, and polycystic ovary disease”
> “Following a 5% reduction of body mass index (BMI), measured as weight in kilograms divided by height in meters squared (kg/m2), adults with a baseline BMI of 30 kg/m2 are estimated to spend 7% less on health care, with the magnitude of benefit correlating to the magnitude of weight reduction”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.6.1-7"></a>

##### Regulatory primary endpoint for weight-reduction drugs

> “The efficacy of a weight-reduction drug in adults should be assessed by analyses of mean”
> “percentage change from baseline body weight in the investigational drug group versus the”
> “control group.”
> “In general, a drug is considered effective for weight reduction and maintenance in patients with”
> “obesity or overweight with comorbidities if, after 1 year of treatment at the maintenance dosage,”
> “the difference in mean percentage weight reduction between the investigational drug and control-”
> “treated groups is at least 5% and the difference is statistically significant.”

Source: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="topic-3.1.5.6.1-8"></a>

##### Categorical responder endpoints: regulatory caution

> “responder analyses may inappropriately exaggerate treatment effects”
> “responder analyses for the evaluation of weight reduction are generally not recommended.”

Source: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### Sample size calculation

> “Sample size of 29 in active and placebo groups was estimated to achieve 84% power to reject the null hypothesis of equal means when the population mean difference (percent change from baseline) between treatment groups is 2.6% with standard deviations (SD) of 3.3% for each treatment group with a significance level (alpha) of 0.05 using a two‐sided, two‐sample t‐test.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.7.1-2"></a>

##### Planned enrollment of approximately 125 participants

> “The 13-week trial will enroll approximately 125 adults who are obese (BMI ≥30 kg/m2), or adults who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.”

Source: [Viking Therapeutics VENTURE initiation release (2023)](https://ir.vikingtherapeutics.com/2023-09-06-Viking-Therapeutics-Announces-Initiation-of-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="topic-3.1.5.7.1-3"></a>

##### Enrollment increased to 176 participants

> “Due to heightened clinician and patient interest, the trial's enrollment size was increased to 176 from the original target.”

Source: [Viking Therapeutics VENTURE enrollment release (2023)](https://ir.vikingtherapeutics.com/2023-10-23-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="topic-3.1.5.7.1-4"></a>

##### Participants randomized and analyzed

> “In total, 176 participants were randomized into the study, with approximately 35 participants randomized to placebo or each active treatment group (Figure 1).”
> “The safety population (N = 175) excludes one participant in the 10 mg group who did not receive treatment and the mITT population used for efficacy analyses (N = 174) excludes that participant and one participant in the placebo group who did not have an evaluable post‐baseline assessment.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

##### Randomized, modified intent-to-treat, and safety populations

> “The randomized population includes all participants who were randomized into the study.”
> “The modified intent‐to‐treat (mITT) population is defined as all participants within the ITT population who had at least one baseline and post‐baseline body weight assessment and received at least one dose of study drug.”
> “The safety population is defined as all randomized participants who received at least one dose of study drug.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.7.2-2"></a>

##### Follow-up subset with week 19 data

> “Weight loss by week and dose in subgroup with follow‐up visits (19 weeks, N = 75).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.7.2-3"></a>

##### Pharmacokinetic subset used for the off-treatment follow-up analysis

> “Pharmacokinetic subset, includes 75 patients (n=63 VK2735; n=12 placebo).”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.5.7.2-4"></a>

##### Cardiovascular risk analysis subset

> “CVD risk subset n=143”
> “Placebo n=20, VK2735 n=90.”

Source: [Chung et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Chung_EISPOR_2026_VENTURE_Predicted_CV_Risk_poster-FINAL.pdf)

<a id="topic-3.1.5.7.2-5"></a>

##### Mixed model for repeated measures for the primary endpoint

> “Percent change from baseline was analyzed using a mixed model for repeated measures (MMRM) approach with baseline treatment, visit, and treatment*visit interaction as factors and baseline weight as a covariate.”
> “If there were multiple weights on a particular day, the average of measurements on that day was used.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.7.2-6"></a>

##### Handling of data after treatment discontinuation and missing data

> “Prior to performing the model, any assessments taken after treatment discontinuation +9 days were set to missing.”
> “The MMRM model used a likelihood‐based approach to manage missing data, assuming data were missing completely at random or missing at random.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.7.2-7"></a>

##### Multiplicity control and supportive analyses

> “All tests were two‐sided and conducted at a significance level of 0.05.”
> “A step‐down closed testing procedure was utilized to preserve the family‐wise type I error at 0.05 and each dose group was tested versus placebo in the following order: VK2735 15, 10, 5, and 2.5 mg.”
> “A nonparametric Wilcoxon rank sum test was also used as a supportive analysis.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.7.2-8"></a>

##### Logistic regression for categorical weight-reduction endpoints

> “The odds ratios, CI, and p values were from logistic regression models with treatment as the factor and baseline weight as the covariate.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.7.2-9"></a>

##### Exploratory shift analyses: observed values without imputation

> “Observed values, no imputation for missing data.”
> “Logistic regression models with treatment as the factor and baseline specified metabolic data as the covariate.”

Source: [Viking Therapeutics ObesityWeek 2025 release (2025)](https://ir.vikingtherapeutics.com/2025-11-06-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-in-Presentation-at-ObesityWeek-R-2025)

<a id="topic-3.1.5.7.2-10"></a>

##### Post hoc predicted cardiovascular risk model

> “These post hoc analyses show the predicted 10-year CVD, ASCVD, and heart failure risk”
> “MMRM model; dependent variable is % change of risk from baseline.”
> “Participants younger than 30, older than 79, or with any pre-existing CVD were excluded.”

Source: [Chung et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Chung_EISPOR_2026_VENTURE_Predicted_CV_Risk_poster-FINAL.pdf)

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

##### Study completion and reasons for early study discontinuation

> “Overall, 167 of the 176 randomized participants (95%) completed the study.”
> “The reasons for early study discontinuation were AEs (n = 3), withdrawal by participant (n = 3), loss to follow‐up (n = 2), and death (n = 1; Figure 1).”
> “A total of 24 of 176 participants (14%) discontinued the treatment early (Figure 1).”
> “The most common reason for early treatment discontinuation was AEs (15/176 participants [8.5%]).”
> “Patients could discontinue treatment and remain in the study.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.1-2"></a>

##### Early treatment and study discontinuation by dose arm, safety population

| Measure, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Discontinued treatment early | “5 (14)” | “2 (6)” | “4 (11)” | “5 (14)” | “7 (20)” |
| Discontinued study early | “2 (6)” | “1 (3)” | “1 (3)” | “2 (6)” | “2 (6)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.1-3"></a>

##### Discontinuation as reported in the topline release

> “A total of 23 patients (13%) discontinued treatment in the study, 5 (14%) in the placebo cohort and 18 (13%) among VK2735-treated cohorts.”

Source: [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

##### Demographic and clinical characteristics by dose arm, randomized population

> “Groups were well matched for baseline characteristics in the randomized population (Table 1), with no significant differences between groups for any parameter.”
> “The majority of participants were non‐Hispanic, White, and female, and the mean age was approximately 50 years.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Characteristic | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 36) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Age, years, mean (SD) | “47.6 (16.36)” | “49.7 (13.90)” | “51.8 (14.10)” | “47.1 (13.40)” | “51.3 (15.41)” |
| Age 65 years or older, n (%) | “4 (11.4)” | “8 (22.9)” | “8 (22.9)” | “4 (11.1)” | “8 (22.9)” |
| Female, n (%) | “29 (82.9)” | “27 (77.1)” | “23 (65.7)” | “24 (66.7)” | “27 (77.1)” |
| White, n (%) | “26 (74.3)” | “28 (80.0)” | “31 (88.6)” | “26 (72.2)” | “28 (80.0)” |
| Black or African American, n (%) | “8 (22.9)” | “7 (20.0)” | “2 (5.7)” | “10 (27.8)” | “6 (17.1)” |
| Hispanic or Latino, n (%) | “7 (20.0)” | “5 (14.3)” | “7 (20.0)” | “6 (16.7)” | “5 (14.3)” |
| Weight, kg, mean (SD) | “104.48 (22.18)” | “103.09 (19.01)” | “98.32 (13.18)” | “102.98 (18.27)” | “101.05 (18.91)” |
| BMI, kg/m2, mean (SD) | “38.88 (6.33)” | “38.03 (5.56)” | “35.86 (4.03)” | “36.62 (4.18)” | “36.63 (5.25)” |
| Prediabetes, n (%) | “14 (40.0)” | “21 (60.0)” | “21 (60.0)” | “16 (44.4)” | “16 (45.7)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.2-2"></a>

##### Metabolic syndrome at baseline by dose arm

| Arm | MetS at baseline, n/N (%) |
| --- | --- |
| Placebo | “18/34 (53)” |
| VK2735 2.5 mg | “21/35 (60)” |
| VK2735 5.0 mg | “22/35 (63)” |
| VK2735 10 mg | “14/35 (40)” |
| VK2735 15 mg | “13/35 (37)” |
| All VK2735 | “70/140 (50)” |

Source: [Bays et al. (2025)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Impact-of-Subcutaneous-VK2735-on-Weight-Prediabetes-and-Cardiometabolic-Status-The-VENTURE-Study.pdf)

<a id="topic-3.1.5.8.2-3"></a>

##### Baseline cardiovascular risk factors in the cardiovascular risk analysis subset

| Characteristic | Placebo (n=27) | All VK2735 (n=116) |
| --- | --- | --- |
| Age, years, mean (SD) | “51.9 (12.2)” | “51.8 (12.1)” |
| Class 3 obesity, BMI 40 or higher, n (%) | “13 (48.2)” | “27 (23.3)” |
| Current smoker, n (%) | “2 (7.4)” | “15 (12.9)” |
| Current statin user, n (%) | “5 (18.5)” | “30 (25.9)” |
| Current hypertension medication user, n (%) | “12 (44.4)” | “40 (34.5)” |

Source: [Chung et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Chung_EISPOR_2026_VENTURE_Predicted_CV_Risk_poster-FINAL.pdf)

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

##### Primary endpoint: percent change in body weight at week 13 by dose, mITT population

> “Statistically significant differences in the primary outcome of percent change of weight from baseline to Week 13 were observed for all active treatment groups (−9.1% to −14.7%, vs. −1.7% for placebo) in the mITT population (Table 2, Figure 2A).”
> “Results from the Wilcoxon rank sum test were consistent with the primary efficacy analysis.”
> “A dose response was observed for all efficacy measures.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Measure | Placebo (n = 34) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Baseline weight, kg, mean (SD) | “105.3 (22.00)” | “103.1 (19.00)” | “98.3 (13.18)” | “103.4 (18.40)” | “101.0 (18.91)” |
| Percent change from baseline, LS mean (95% CI) | “−1.7 (−3.03, −0.30)” | “−9.1 (−10.43, −7.76)” | “−10.9 (−12.25, −9.55)” | “−12.9 (−14.30, −11.56)” | “−14.7 (−16.11, −13.38)” |
| LS mean difference from placebo, percentage points (95% CI) | Not applicable | “−7.43 (−9.34, −5.52)” | “−9.23 (−11.15, −7.31)” | “−11.26 (−13.20, −9.33)” | “−13.08 (−15.01, −11.15)” |
| p value vs placebo | Not applicable | “< 0.0001” | “< 0.0001” | “< 0.0001” | “< 0.0001” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.3-2"></a>

##### Secondary endpoint: change in body weight in kilograms at week 13 by dose

| Measure | Placebo (n = 34) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Change from baseline, kg, LS mean (95% CI) | “−1.8 (−3.09, −0.44)” | “−9.2 (−10.46, −7.86)” | “−10.7 (−11.97, −9.33)” | “−13.3 (−14.61, −11.94)” | “−14.6 (−15.96, −13.30)” |
| LS mean difference from placebo, kg (95% CI) | Not applicable | “−7.40 (−9.26, −5.54)” | “−8.88 (−10.76, −7.01)” | “−11.51 (−13.39, −9.63)” | “−12.86 (−14.74, −10.99)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.3-3"></a>

##### Categorical weight reduction of at least 5%, 10%, and 15% at week 13 by dose

> “In the active treatment groups, 93% (130/140) of participants had a ≥ 5% weight reduction, compared with 12% (4/34) of participants with placebo treatment.”
> “A dose response was seen at the ≥ 10% weight loss threshold.”
> “The highest two doses (10 and 15 mg) resulted in the largest percentage of patients with a ≥ 15% decrease in body weight.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Threshold and statistic | Placebo (n = 34) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| At least 5% reduction, n (%) | “4 (11.5)” | “28 (80.8)” | “34 (97.0)” | “33 (93.8)” | “35 (100)” |
| At least 5%, odds ratio vs placebo (95% CI) | Not applicable | “26.7 (6.9, 103.2)” | “148.9 (20.8, > 999.9)” | “84.6 (15.6, 457.2)” | “454.1 (23.3, > 999.9)” |
| At least 10% reduction, n (%) | “1 (3.0)” | “14 (40.1)” | “23 (65.1)” | “25 (70.4)” | “31 (89.1)” |
| At least 10%, odds ratio vs placebo (95% CI) | Not applicable | “23.6 (2.8, 197.5)” | “60.2 (7.1, 509.3)” | “91.5 (10.4, 806.8)” | “315.5 (30.6, > 999.9)” |
| At least 10%, p value vs placebo | Not applicable | “0.0036” | “0.0002” | “< 0.0001” | “< 0.0001” |
| At least 15% reduction, n (%) | “0” | “4 (12.8)” | “4 (11.6)” | “11 (31.2)” | “15 (41.5)” |
| At least 15%, odds ratio vs placebo (95% CI) | Not applicable | “11.2 (0.5, 228.2)” | “9.1 (0.4, 188.6)” | “35.9 (1.9, 677.1)” | “52.3 (2.8, 982.7)” |
| At least 15%, p value vs placebo | Not applicable | “0.1163” | “0.1533” | “0.0169” | “0.0082” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.3-4"></a>

##### Topline release: placebo-adjusted weight change and 10% responders by dose

| Measure | Placebo (n=34) | 2.5 mg (n=35) | 5 mg (n=35) | 10 mg (n=35) | 15 mg (n=35) |
| --- | --- | --- | --- | --- | --- |
| Placebo-adjusted mean percent change from baseline | Not applicable | “-7.4 %” | “-9.2 %” | “-11.3 %” | “-13.1 %” |
| Percent reporting at least 10% weight loss | “4 %” | “39 %” | “62 %” | “70 %” | “88 %” |

Source: [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="topic-3.1.5.8.3-5"></a>

##### Weight-loss trajectory: separation from placebo at week 1 and no plateau at week 13

> “Statistically significant differences compared to both baseline and placebo were observed for all doses starting at Week one and continuing throughout the 13-week treatment period.”
> “Reductions in body weight were progressive through the course of the study, with no plateau observed for weight loss at 13 weeks.”

Source: [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="topic-3.1.5.8.3-6"></a>

##### Off-treatment follow-up: weight loss persisting 4 and 7 weeks after the last dose

> “In the subset of participants who had post‐dose follow‐up visits, persistent weight loss was seen at 4‐ and 7‐week follow‐up visits (Weeks 16 and 19, respectively), shown in Figure 2B.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

> “The results showed that all cohorts receiving VK2735 maintained the majority of their weight loss four weeks after receiving the final dose of VK2735 in the study (p<0.0001 vs. baseline and placebo, all cohorts).”
> “In addition, follow-up assessments seven weeks after administration of the final dose demonstrated continued maintenance effects, with over 80% of the original weight loss maintained in the combined PK subset (p<0.0005 vs. baseline and placebo, all cohorts).”

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

| Time after final dose | 2.5 mg (n=17) | 5 mg (n=17) | 10 mg (n=18) | 15 mg (n=11) | Combined VK2735 arms |
| --- | --- | --- | --- | --- | --- |
| Proportion of weight loss maintained, four weeks post final dose | “98 %” | “92 %” | “92 %” | “96 %” | “94 %” |
| Proportion of weight loss maintained, seven weeks post final dose | “91 %” | “82 %” | “75 %” | “87 %” | “83 %” |

Source: [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024)

<a id="topic-3.1.5.8.3-7"></a>

##### Pharmacokinetics in the follow-up subset

> “PK, exposure profile suggests monthly dosing may be feasible”

Source: [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf)

| Representative PK parameter, VK2735 5.0 mg | Value |
| --- | --- |
| Cmax, ng/mL | “1,120” |
| AUC0-168, ng*h/mL | “158,000” |
| Half-life, h | “171” |

Source: [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf)

<a id="topic-3.1.5.8.3-8"></a>

##### Other anthropometric measures: BMI and hip circumference

> “There was a dose‐dependent decrease from baseline for other measures of weight loss, including change in BMI and hip circumference (Table S3).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.3-9"></a>

##### Glycemic status: shift from prediabetes to normoglycemia and change in glucose and HbA1c

> “Of the 74 participants who had prediabetes at baseline, 58 (78%) shifted to normoglycemic at Week 13 in the active treatment groups and none shifted from prediabetes to diabetes.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Measure | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 36) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Prediabetes at baseline, n | “14” | “21” | “21” | “16” | “16” |
| Shift to normoglycemic, n (%) | “4 (28.6)” | “17 (81.0)” | “16 (76.2)” | “10 (62.5)” | “15 (93.8)” |
| Shift to diabetes, n (%) | “1 (7.1)” | “0” | “0” | “0” | “0” |
| Fasting glucose, mg/dL, baseline mean (SD) | “99.37 (9.932)” | “100.31 (9.320)” | “99.77 (9.478)” | “97.97 (8.687)” | “99.06 (7.685)” |
| Fasting glucose, mg/dL, change from baseline, LS mean (SE) | “−0.37 (1.475)” | “−10.66 (1.439)” | “−10.23 (1.424)” | “−9.46 (1.424)” | “−10.85 (1.456)” |
| HbA1c, %, baseline mean (SD) | “5.49 (0.361)” | “5.51 (0.360)” | “5.43 (0.399)” | “5.50 (0.357)” | “5.50 (0.312)” |
| HbA1c, %, change from baseline, LS mean (SE) | “0.03 (0.041)” | “−0.29 (0.040)” | “−0.27 (0.040)” | “−0.27 (0.039)” | “−0.36 (0.040)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.3-10"></a>

##### Metabolic syndrome resolution at week 13, exploratory analysis

> “Similarly, 68% of VK2735-treated patients who met the criteria for MetS at baseline were no longer considered to have the syndrome at Week 13, as compared to 38% for placebo patients (p=0.02).”

Source: [Viking Therapeutics ObesityWeek 2025 release (2025)](https://ir.vikingtherapeutics.com/2025-11-06-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-in-Presentation-at-ObesityWeek-R-2025)

| Measure | Placebo | 2.5 mg | 5 mg | 10 mg | 15 mg | Combined VK2735 arms |
| --- | --- | --- | --- | --- | --- | --- |
| MetS at baseline, n | “16” | “21” | “21” | “13” | “10” | “65” |
| Shifting to no MetS at week 13, n (%) | “6 (38 %)” | “14 (67 %)” | “14 (67 %)” | “10 (77 %)” | “6 (60 %)” | “44 (68 %)” |
| p value vs placebo | Not applicable | “0.1102” | “0.0217” | “0.0182” | “0.3892” | “0.0244” |

Source: [Viking Therapeutics ObesityWeek 2025 release (2025)](https://ir.vikingtherapeutics.com/2025-11-06-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-in-Presentation-at-ObesityWeek-R-2025)

> “Participants receiving VK2735 (combined tx groups) had significantly greater odds of transitioning from meeting MetS criteria at BL to not meeting them by week 13 compared to placebo (OR: 6.74; p=0.02)”
> “Participants receiving VK2735 (combined tx groups) had significantly greater odds of transitioning from prediabetes at BL to normoglycemia by week 13 compared to placebo (OR: 9.1; p=0.0008)”

Source: [Bays et al. (2025)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Impact-of-Subcutaneous-VK2735-on-Weight-Prediabetes-and-Cardiometabolic-Status-The-VENTURE-Study.pdf)

<a id="topic-3.1.5.8.3-11"></a>

##### Blood pressure change at week 13 by dose

| Measure | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 36) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Systolic blood pressure, mmHg, baseline mean (SD) | “125.10 (13.963)” | “126.20 (14.754)” | “128.60 (15.253)” | “122.64 (13.764)” | “123.36 (14.531)” |
| Systolic blood pressure, mmHg, change from baseline, LS mean (SE) | “−4.20 (1.993)” | “−6.87 (1.906)” | “−6.71 (1.931)” | “−7.04 (1.936)” | “−10.97 (2.000)” |
| Diastolic blood pressure, mmHg, baseline mean (SD) | “80.93 (9.169)” | “81.56 (9.491)” | “82.91 (7.904)” | “79.00 (9.420)” | “78.39 (7.332)” |
| Diastolic blood pressure, mmHg, change from baseline, LS mean (SE) | “−1.68 (1.286)” | “−3.27 (1.229)” | “−4.34 (1.246)” | “−2.37 (1.247)” | “−5.16 (1.290)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.3-12"></a>

##### Lipids and high-sensitivity C-reactive protein at week 13

> “Lipid markers generally declined over the 13‐week study in the active treatment group (N = 141).”
> “Only total cholesterol had a p value less than 0.05 versus placebo (p = 0.0396) in this time frame.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| hsCRP, mg/L | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Baseline, median | “4.50” | “3.50” | “4.00” | “3.40” | “3.70” |
| Change from baseline, median | “0.20” | “0.10” | “−0.30” | “−0.10” | “−0.75” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.3-13"></a>

##### Lipids and other cardiometabolic parameters, combined VK2735 arms versus placebo

| Parameter | Mean difference, VK2735 compared with placebo | Standardized mean difference (95% CI) |
| --- | --- | --- |
| Total cholesterol, mg/dL | “–8.03” | “–0.26 (–0.75, 0.22)” |
| Triglycerides, mg/dL | “–11.90” | “–0.22 (–0.70, 0.27)” |
| LDL, mg/dL | “–3.98” | “–0.14 (–0.63, 0.34)” |
| HbA1c, % | “–0.32” | “–1.49 (–2.01, –0.97)” |
| BMI, kg/m² | “–3.52” | “–2.32 (–2.90, –1.75)” |
| SBP, mmHg | “–2.40” | “–0.20 (–0.69, 0.28)” |

Source: [Chung et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Chung_EISPOR_2026_VENTURE_Predicted_CV_Risk_poster-FINAL.pdf)

<a id="topic-3.1.5.8.3-14"></a>

##### Predicted 10-year cardiovascular risk at week 13, post hoc analysis

| Predicted 10-year risk | LS mean difference in percent change from baseline, VK2735 vs placebo (95% CI) | P value |
| --- | --- | --- |
| Cardiovascular disease | “–4.14 (–17.22, 8.94)” | “.532” |
| Atherosclerotic cardiovascular disease | “–6.67 (–19.44, 6.09)” | “.303” |
| Heart failure | “–16.21 (–27.37, –5.06)” | “.005” |

Source: [Chung et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Chung_EISPOR_2026_VENTURE_Predicted_CV_Risk_poster-FINAL.pdf)

<a id="topic-3.1.5.8.3-15"></a>

##### BMI category shifts from baseline to week 13, exploratory analysis

> “At week 13, the majority (104/140; 74%) of the combined VK2735 group demonstrated ≥1 BMI category improvement versus 5/34 (15%) in the placebo group”
> “No VK2735-treated participants experienced worsening BMI category; one placebo participant demonstrated worsening BMI category”

Source: [Bays et al. (2026b)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Bays_OW2026_VENTURE_CM_Impact_poster-FINAL.pdf)

| Baseline category and transition | VK2735 combined | Placebo |
| --- | --- | --- |
| Class III obesity at baseline, n | “n=35” | “n=15” |
| Class III, transitioning to Class II | “57 %” | “13 %” |
| Class III, transitioning to Class I | “11 %” | “0 %” |
| Class III, no change in obesity class | “31 %” | “87 %” |
| Class II obesity at baseline, n | “n=51” | “n=10” |
| Class II, transitioning to Class I | “80 %” | “20 %” |
| Class II, transitioning to overweight | “2 %” | “0 %” |
| Class II, no change in obesity class | “18 %” | “80 %” |
| Class I obesity at baseline, n | “n=46” | “n=8” |
| Class I, transitioning to overweight | “65 %” | “12 %” |
| Class I, transitioning to normal weight | “9 %” | “0 %” |
| Class I, no change in obesity class | “26 %” | “75%” |
| Overweight at baseline, n | “n=8” | “n=1” |
| Overweight, transitioning to normal weight | “50 %” | “0 %” |

Source: [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026)

<a id="topic-3.1.5.8.3-16"></a>

##### Cardiometabolic markers by BMI category change among VK2735-treated participants

| Marker, mean (SD) | Baseline (N=124) | Change with at least one BMI category improvement (N=89) | Change with no BMI category change (N=35) |
| --- | --- | --- | --- |
| Hemoglobin A1C, % | “5.49 (0.36)” | “-0.34 (0.25)” | “-0.25 (0.17)” |
| Glucose, mg/dL | “99.8 (8.77)” | “-12.4 (9.69)” | “-10.1 (8.56)” |
| Triglycerides, mg/dL | “122.1 (62.16)” | “-20.1 (56.76)” | “-2.2 (52.40)” |
| Waist circumference, cm | “112.7 (11.34)” | “-10.1 (5.90)” | “-7.7 (4.24)” |
| Systolic blood pressure, mmHg | “124.5 (14.53)” | “-9.0 (12.26)” | “-6.0 (13.47)” |
| Diastolic blood pressure, mmHg | “80.1 (8.69)” | “-4.2 (8.27)” | “-2.8 (8.97)” |
| LDL cholesterol, mg/dL | “116.7 (33.12)” | “-12.3 (27.61)” | “-6.9 (23.45)” |

Source: [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026)

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

##### Overall treatment-emergent adverse events and severity

> “Of the 175 participants in the safety population, 142 (81.1%) experienced at least one TEAE of any type, and 120 of 175 (68.6%) experienced a total of 356 drug‐related TEAEs (Table 3).”
> “Most drug‐related TEAEs were mild or moderate; 71 of 175 participants (40.6%) experienced a maximum severity of grade 1 (mild), 41 (23.4%) grade 2 (moderate), 8 (4.6%) grade 3 (severe), and no participants experienced grade 4 (life‐threatening) AEs.”
> “The most common study drug‐related TEAEs were nausea (64/175 participants [36.6%]), constipation (37/175 [21.1%]), and vomiting (22/175 [12.6%]).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Event, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Any TEAE | “24 (69)” | “25 (71)” | “31 (89)” | “30 (86)” | “32 (91)” |
| Drug-related TEAE | “16 (46)” | “21 (60)” | “27 (77)” | “26 (74)” | “30 (86)” |
| Treatment-emergent serious adverse event | “1 (3)” | “2 (6)” | “2 (6)” | “2 (6)” | “1 (3)” |
| Death | “0” | “0” | “0” | “0” | “1 (3)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-2"></a>

##### Discontinuation due to adverse events by dose

> “In total, 16 of 175 participants (9.1%) experienced at least one TEAE leading to withdrawal of the study drug.”
> “The most common TEAEs experienced by these participants were nausea (five participants), vomiting (four participants), diarrhea (two participants), and headache (two participants).”
> “No other AEs were experienced by more than one participant who discontinued treatment due to TEAEs.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Event, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| TEAE leading to treatment discontinuation | “0” | “1 (3)” | “4 (11)” | “4 (11)” | “7 (20)” |
| TEAE leading to study discontinuation | “0” | “0” | “1 (3)” | “1 (3)” | “1 (3)” |
| Drug-related TEAE leading to study discontinuation | “0” | “0” | “0” | “0” | “1 (3)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-3"></a>

##### Gastrointestinal adverse events by dose, all causality

| Preferred term, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Gastrointestinal disorders, any | “13 (37)” | “18 (51)” | “23 (66)” | “25 (71)” | “29 (83)” |
| Nausea | “7 (20)” | “9 (26)” | “16 (46)” | “13 (37)” | “22 (63)” |
| Constipation | “4 (11)” | “7 (20)” | “10 (29)” | “9 (26)” | “10 (29)” |
| Diarrhea | “3 (9)” | “11 (31)” | “6 (17)” | “7 (20)” | “4 (11)” |
| Vomiting | “0” | “3 (9)” | “6 (17)” | “6 (17)” | “10 (29)” |
| Gastroesophageal reflux disease | “1 (3)” | “2 (6)” | “5 (14)” | “4 (11)” | “6 (17)” |
| Abdominal pain | “1 (3)” | “1 (3)” | “2 (6)” | “1 (3)” | “2 (6)” |
| Eructation | “0” | “2 (6)” | “0” | “0” | “3 (9)” |
| Decreased appetite | “0” | “2 (6)” | “5 (14)” | “9 (26)” | “6 (17)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-4"></a>

##### Drug-related gastrointestinal adverse events by severity and dose

> “The majority of GI‐related TEAEs were mild or moderate in severity and no grade 4 or 5 TEAEs were observed (Table 4).”
> “Nausea was the most common GI TEAE and had the highest severity (Tables 3 and 4).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Event and severity, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Any gastrointestinal disorder, mild | “8 (23)” | “8 (23)” | “14 (40)” | “13 (37)” | “16 (46)” |
| Any gastrointestinal disorder, moderate | “4 (11)” | “7 (20)” | “9 (26)” | “7 (20)” | “10 (29)” |
| Any gastrointestinal disorder, severe | “0” | “1 (3)” | “0” | “1 (3)” | “3 (9)” |
| Nausea, mild | “7 (20)” | “5 (14)” | “11 (31)” | “8 (23)” | “15 (43)” |
| Nausea, moderate | “0” | “2 (6)” | “5 (14)” | “4 (11)” | “7 (20)” |
| Constipation, mild | “2 (6)” | “3 (9)” | “8 (23)” | “6 (17)” | “9 (26)” |
| Constipation, moderate | “2 (6)” | “2 (6)” | “1 (3)” | “2 (6)” | “1 (3)” |
| Vomiting, mild | “0” | “2 (6)” | “4 (11)” | “5 (14)” | “5 (14)” |
| Vomiting, moderate | “0” | “0” | “2 (6)” | “0” | “3 (9)” |
| Diarrhea, mild | “2 (6)” | “4 (11)” | “5 (14)” | “2 (6)” | “1 (3)” |
| Diarrhea, moderate | “0” | “2 (6)” | “1 (3)” | “0” | “3 (9)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-5"></a>

##### Time course of gastrointestinal adverse events

> “GI AEs were generally observed early in the study and subsided over time (Figure 3).”
> “No dose‐dependent increase in GI TEAEs was observed after initial dosing (Figure 3).”
> “Given that the 5 mg dose had a higher GI TEAE rate than the 10 mg dose, there does not seem to be a dose‐dependent increase in GI TEAEs if a 2.5 mg starting dose is used at the beginning of the titration phase.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

> “GI-related adverse events were generally observed early in treatment, with decreasing frequency upon repeat dosing.”
> “Across the combined VENTURE study arms, the weekly rate of nausea did not exceed 5% at any point after the first week of treatment.”

Source: [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="topic-3.1.5.8.5-6"></a>

##### Topline release summary of gastrointestinal tolerability

> “The majority of TEAEs that were gastrointestinal (GI) in nature (95%) were also reported as mild or moderate.”
> “Nausea was reported among patients receiving both VK2735 (43%) and placebo (20%).”
> “Among subjects receiving VK2735, the majority of reported nausea (68%) was characterized as mild (32% moderate, none severe).”
> “Vomiting was reported in 25/140 (18%) VK2735-treated patients compared with none reported among patients receiving placebo.”

Source: [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)

<a id="topic-3.1.5.8.5-7"></a>

##### Serious adverse events and death

> “A total of 8 of 175 participants (4.6%) experienced a total of 12 TESAEs.”
> “Ten of the twelve TESAEs were considered unrelated to the study drug by investigators.”
> “One participant in the 5.0 mg dose group experienced two drug‐related TESAEs, atrial fibrillation (possibly related) and dehydration (probably related), which led to study discontinuation.”
> “One (0.6%) participant died during the study.”
> “head trauma from a fall”
> “with underlying causes of hypertension and hyperlipidemia, and it was assessed as not related to the study drug.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-8"></a>

##### Adverse events of special interest: pancreatitis, gallbladder events, and injection site reactions

> “A total of 27 TEAEs of special interest, injection site reaction being the most common, were experienced by 21 of 175 participants (12.0%; Table 3).”
> “Gallbladder associated AEs of special interest were cholecystitis and cholelithiasis.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Event of special interest, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Pancreatitis | “0” | “0” | “0” | “0” | “0” |
| Gallbladder associated events | “0” | “1 (3)” | “0” | “0” | “1 (3)” |
| Injection site reactions | “3 (9)” | “2 (6)” | “5 (14)” | “5 (14)” | “4 (11)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-9"></a>

##### Anti-drug antibodies at week 13

> “At Week 13, anti‐drug antibodies were detected in between 9% (2.5 mg group) and 23% (10 mg group) of participants in any treatment group (Table 3).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

| Measure | 2.5 mg | 5.0 mg | 10 mg | 15 mg |
| --- | --- | --- | --- | --- |
| Anti-VK2735 antibody positive at week 13, n/N (%) | “3/34 (9)” | “4/34 (12)” | “8/35 (23)” | “5/32 (16)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-10"></a>

##### Heart rate change at week 13 by dose

| Heart rate, bpm | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 36) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Baseline, mean (SD) | “74.2 (11.01)” | “69.9 (10.46)” | “70.2 (10.45)” | “71.7 (8.53)” | “69.3 (9.94)” |
| Change from baseline, mean (SD) | “1.4 (12.15)” | “3.3 (11.94)” | “6.1 (9.33)” | “9.3 (8.51)” | “6.9 (8.43)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-3.1.5.8.5-11"></a>

##### Heart rate and blood pressure as reported on the 2024 congress poster

| Vital sign | Placebo | 2.5 mg | 5 mg | 10 mg | 15 mg |
| --- | --- | --- | --- | --- | --- |
| Heart rate, bpm, baseline | “65.7” | “63.5” | “66.9” | “64.3” | “63.9” |
| Heart rate, bpm, mean change at week 13 | “4.4” | “3.8” | “5.0” | “10.8” | “7.1” |
| Systolic blood pressure, mmHg, mean change at week 13 | “-4.4” | “-7.4” | “-8.8” | “-5.4” | “-9.6” |
| Diastolic blood pressure, mmHg, mean change at week 13 | “-2.2” | “-3.7” | “-5.5” | “-1.5” | “-4.3” |

Source: [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf)

<a id="topic-3.1.5.8.5-12"></a>

##### Other selected adverse events by dose: hypotension, dizziness, fatigue, lipase, and hyperthyroidism

| Preferred term, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| Hypotension | “0” | “0” | “1 (3)” | “1 (3)” | “2 (6)” |
| Dizziness | “1 (3)” | “1 (3)” | “2 (6)” | “0” | “4 (11)” |
| Fatigue | “1 (3)” | “1 (3)” | “5 (14)” | “2 (6)” | “4 (11)” |
| Headache | “4 (11)” | “1 (3)” | “4 (11)” | “2 (6)” | “4 (11)” |
| Lipase increased | “0” | “1 (3)” | “2 (6)” | “0” | “0” |
| Hyperthyroidism | “0” | “0” | “0” | “2 (6)” | “0” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary: limitations of the VENTURE evidence

VENTURE was a phase 2 dose-finding trial of 13 weeks of treatment in 176 randomized participants, about 35 per arm, conducted at 20 United States sites. The authors state that it was “limited in size and duration” and “not powered to determine statistical significance for differences between treatment groups for most parameters.” The sample size calculation of 29 participants per arm was based on a two-sample t-test. A 13-week result does not address the FDA draft guidance benchmark, which assesses effectiveness after 1 year of treatment at the maintenance dosage. The topline release reported no weight-loss plateau at week 13, and the authors state that “Maximal therapeutic levels were likely not yet achieved in this limited duration study.”

People with diabetes were excluded, BMI above 50 kg/m2 was excluded, and the randomized population was mostly female and White, with between 65.7% and 82.9% female and between 72.2% and 88.6% White participants per arm. The 15 mg arm started at 5.0 mg while the other arms started at 2.5 mg, and the authors state that the “titration schedule and dosing, will be changed to optimize tolerability in future studies.”

The primary analysis was a mixed model for repeated measures in the modified intent-to-treat population (174 participants), with assessments more than 9 days after treatment discontinuation set to missing and data assumed missing at random. This corresponds to an on-treatment estimand; no treatment-policy analysis that retains off-treatment weights was reported. Off-treatment weight data at weeks 16 and 19 were reported only for a pharmacokinetic subset of 75 participants (63 VK2735, 12 placebo). Responder analyses, which the FDA draft guidance states may “inappropriately exaggerate treatment effects”, were secondary endpoints.

Reported figures differ between documents. The topline release reported 23 participants (13%) discontinuing treatment and 10% responder proportions of 4%, 39%, 62%, 70%, and 88%, while the publication reported 24 of 176 (14%) and 3.0%, 40.1%, 65.1%, 70.4%, and 89.1%. Baseline heart rate on the 2024 poster (63.5 to 66.9 bpm) differs from the publication (69.3 to 74.2 bpm), as does the week 13 heart rate change (3.8 to 10.8 bpm versus 3.3 to 9.3 bpm in active arms). Mean heart rate increased by up to 9.3 bpm in the 10 mg arm versus 1.4 bpm with placebo in the publication. Treatment discontinuation due to adverse events rose with dose, from 1 of 35 (3%) at 2.5 mg to 7 of 35 (20%) at 15 mg, with none on placebo.

The metabolic syndrome, BMI category, and predicted cardiovascular risk analyses were exploratory or post hoc, reported in company releases and congress posters without peer review, used observed values without imputation, and reported no adjustment for multiplicity. The cardiovascular risk subset comprised 143 participants, of whom 110 (20 placebo, 90 VK2735) entered the risk model, and all authors of that poster are company employees. No health-related quality of life or patient-reported outcome was reported. The trial was funded by Viking Therapeutics, and every author of the publication was a site investigator or a company employee. No results are posted on ClinicalTrials.gov.

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/); [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity); [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf); [Viking Therapeutics ObesityWeek 2024 release (2024)](https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024); [Viking Therapeutics ObesityWeek 2025 release (2025)](https://ir.vikingtherapeutics.com/2025-11-06-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-in-Presentation-at-ObesityWeek-R-2025); [Bays et al. (2026b)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Bays_OW2026_VENTURE_CM_Impact_poster-FINAL.pdf); [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026); [Chung et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/11/Chung_EISPOR_2026_VENTURE_Predicted_CV_Risk_poster-FINAL.pdf); [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download); [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
